Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi
- PMID: 31187704
- DOI: 10.2174/0929867326666190610152934
Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi
Abstract
Chagas disease, caused by the flagellate parasite Trypanosoma cruzi, is a wellknown neglected tropical disease. This parasitic illness affects 6-7 million people and can lead to severe myocarditis and/or complications of the digestive tract. The changes in its epidemiology facilitate co-infection with the Human Immunodeficiency Virus (HIV), making even more difficult the diagnosis and prognosis. The parasitic infection is reactivated in T. cruzi/HIV co-infection, with the appearance of unusual manifestations in the chronic phase and the exacerbation of classical clinical signs. The therapeutic arsenal to treat Chagas disease, in all its clinical forms, is restricted basically to two drugs, benznidazole and nifurtimox. Both drugs are extremely toxic and the therapeutic efficacy is still unclear, making the clinical treatment a huge issue to be solved. Therefore, it seems obvious the necessity of new tangible approaches to combat this illness. In this sense, the repositioning of approved drugs appears as an interesting and viable strategy. The discovery of Human Immunodeficiency Virus Aspartyl Peptidase Inhibitors (HIV-PIs) represented a milestone in the treatment of Acquired Immune Deficiency Syndrome (AIDS) and, concomitantly, a marked reduction in both the incidence and prevalence of important bacterial, fungal and parasitic co-infections was clearly observed. Taking all these findings into consideration, the present review summarizes the promising and beneficial data concerning the effects of HIV-PIs on all the evolutionary forms of T. cruzi and in important steps of the parasite's life cycle, which highlight their possible application as alternative drugs to treat Chagas disease.
Keywords: Chagas disease; HIV-PIs; Trypanosoma cruzi; drug repositioning; mode of action; physiological alterations..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.Mem Inst Oswaldo Cruz. 2022 Mar 16;117:e210386. doi: 10.1590/0074-02760210386. eCollection 2022. Mem Inst Oswaldo Cruz. 2022. PMID: 35293428 Free PMC article.
-
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.PLoS One. 2014 Dec 2;9(12):e113957. doi: 10.1371/journal.pone.0113957. eCollection 2014. PLoS One. 2014. PMID: 25464510 Free PMC article.
-
Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase.BMC Res Notes. 2018 Nov 21;11(1):825. doi: 10.1186/s13104-018-3927-z. BMC Res Notes. 2018. PMID: 30463602 Free PMC article.
-
High-throughput drug repositioning for the discovery of new treatments for Chagas disease.Mini Rev Med Chem. 2015;15(3):182-93. doi: 10.2174/138955751503150312120208. Mini Rev Med Chem. 2015. PMID: 25769967 Review.
-
Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.Curr Med Chem. 2019;26(36):6672-6686. doi: 10.2174/0929867326666190705160637. Curr Med Chem. 2019. PMID: 31284853 Review.
Cited by
-
Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors.Mem Inst Oswaldo Cruz. 2022 Mar 16;117:e210386. doi: 10.1590/0074-02760210386. eCollection 2022. Mem Inst Oswaldo Cruz. 2022. PMID: 35293428 Free PMC article.
-
Cytotoxicity of Essential Oil Cordia verbenaceae against Leishmania brasiliensis and Trypanosoma cruzi.Molecules. 2021 Jul 25;26(15):4485. doi: 10.3390/molecules26154485. Molecules. 2021. PMID: 34361638 Free PMC article.
-
Lopinavir and Nelfinavir Induce the Accumulation of Crystalloid Lipid Inclusions within the Reservosomes of Trypanosoma cruzi and Inhibit Both Aspartyl-Type Peptidase and Cruzipain Activities Detected in These Crucial Organelles.Trop Med Infect Dis. 2021 Jul 1;6(3):120. doi: 10.3390/tropicalmed6030120. Trop Med Infect Dis. 2021. PMID: 34287373 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical